April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
African Descent and Glaucoma Evaluation Study (ADAGES): Rate and Pattern of Rim Area Loss in Normal and Progressing Eyes
Author Affiliations & Notes
  • Naama Hammel
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, CA
  • Andrew J Tatham
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, CA
  • Lucie Sharpsten
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, CA
  • Jeffrey M Liebmann
    School of Medicine, New York University, New York, NY
    Department of Ophthalmology, Einhorn Cilinical Research Center, New York Eye and Ear Infirmary, New York, NY
  • Christopher A Girkin
    School of Medicine, University of Alabama, Birmingham, AL
  • Felipe A Medeiros
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, CA
  • Robert N Weinreb
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, CA
  • Linda M Zangwill
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, CA
  • Footnotes
    Commercial Relationships Naama Hammel, None; Andrew Tatham, Heidelberg Engineering GmbH (F); Lucie Sharpsten, None; Jeffrey Liebmann, Alcon Labortories Inc. (C), Allergan Inc. (C), Allergan Inc. (F), Bausch & Lomb Inc. (C), Bausch & Lomb Inc. (F), Carl Zeiss Meditech Inc. (F), Diopsys Inc. (C), Diopsys Inc. (F), Heidelberg Engineering GmbH (C), Heidelberg Engineering GmbH (F), Merz Pharmaceuticals Inc. (C), Optovue Inc. (F), Quark Pharmaceuticals Inc. (F), Reichert Inc. (F), Sensimed Inc. (F), Topcon Medical Systems Inc. (F), Valeant Pharmaceuticals Inc. (C); Christopher Girkin, Carl Zeiss Meditech Inc. (F), Heidelberg Engineering GmbH (F), SOLX (F); Felipe Medeiros, Alcon Laboratories Inc. (F), Alcon Laboratories Inc. (R), Allergan Inc. (C), Allergan Inc. (F), Allergan Inc. (R), Bausch & Lomb Inc. (F), Carl Zeiss Meditech Inc. (C), Carl Zeiss Meditech Inc. (F), Carl Zeiss Meditech Inc. (R), Heidelberg Engineering GmbH (F), Merck Inc. (F), National Eye Institute (F), Novartis Inc. (C), Reichert Inc. (F), Reichert Inc. (R), Sensimed Inc. (F), Topcon Medical Systems Inc. (F); Robert Weinreb, Aerie Inc. (F), Alcon Laboratories Inc. (C), Allergan Inc. (C), Bausch & Lomb Inc. (C), Carl Zeiss Meditech Inc. (C), Carl Zeiss Meditech Inc. (F), Genentech Inc. (F), Heidelberg Engineering GmbH (F), National Eye Institute (F), Nidek Inc. (F), Novartis Inc. (F), Optovue Inc. (F), Sensimed Inc. (C), Topcon Medical Systems Inc. (C), Topcon Medical Systems Inc. (F); Linda Zangwill, Carl Zeiss Meditech Inc. (F), Heidelberg Engineering GmbH (F), Nidek Inc. (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4768. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Naama Hammel, Andrew J Tatham, Lucie Sharpsten, Jeffrey M Liebmann, Christopher A Girkin, Felipe A Medeiros, Robert N Weinreb, Linda M Zangwill; African Descent and Glaucoma Evaluation Study (ADAGES): Rate and Pattern of Rim Area Loss in Normal and Progressing Eyes. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4768.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To compare the rate and pattern of rim area (RA) loss in normal and glaucomatous subjects of African Descent (AD) and European Descent (ED).

 
Methods
 

Global and sectoral RA was measured using HRTII. Progression of glaucomatous optic disc damage was determined by stereophoto review. The rates of RA loss and %RA loss in normal and progressing glaucomatous eyes were compared using multivariable mixed-effects models.

 
Results
 

506 eyes of 264 normal subjects (139 AD and 125 ED) and 74 progressing glaucoma eyes of 68 subjects (24 AD and 44 ED) were included. Mean age was 47.9 years (range 18.3-85.4) in the normal group and 59.7 years (25.9-80.6) in the progressing group. The median (inter-quartile range) follow-up time was 5.0 years (2.9-6.9) for normal eyes and 8.2 years (7.1-9.9) for progressing eyes. The mean rate of global RA loss was significantly faster in progressing eyes compared with normal eyes for both RA loss (-0.01mm2/year vs. -0.004mm2/year, P=0.000) and %RA loss (-1.03%/year vs. -0.2%/year, P=0.000). For both normal and progressing eyes, the pattern of RA loss and %RA loss was similar; it tended to be faster in the temporal, temporal inferior and temporal superior regions than in the nasal regions. In the normal group, the estimated mean rate of global RA loss and %RA loss were faster in eyes of subjects of ED compared with subjects of AD (-0.0058 mm2/year vs. -0.0025mm2/year, P=0.003, and -0.28%/year vs. -0.09%/year, P=0.074). No statistically significant difference in rate of RA loss or %RA loss was found between progressing eyes of ED and AD subjects.

 
Conclusions
 

Compared with normal eyes, the rate of RA loss was 2.5 times faster and the rate of %RA loss was 5.2 times faster in progressing glaucoma eyes. Given that the pattern of faster loss in temporal sectors was similar in both groups, it is important to evaluate the magnitude of RA loss to help differentiate normal aging from glaucoma progression. In addition, studies assessing the pattern of RNFL damage in healthy eyes are needed to determine whether the faster change in the temporal region is specific to CSLO HRT measurements or to the aging process. The trend of a faster mean rate of RA loss in ED compared to AD normal eyes should be replicated in an independent study.

     
Keywords: 550 imaging/image analysis: clinical • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 413 aging  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×